denosumab
Sign in to saveAlso known as AMG-162
Denosumab, sold under the brand name Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.
Key facts
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- RANK ligand
- Drug.tradename
- Prolia, Xgeva, others
- Drug.MedlinePlus
- a610023
- Drug.DailyMedID
- Denosumab
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Subcutaneous
- Drug.class
- Disease-modifying antirheumatic drug
- Drug.ATC_prefix
- M05
- Drug.ATC_suffix
- BX04
- Drug.biosimilars
- denosumab-bbdz, denosumab-bmwo, denosumab-bnht, denosumab-desu, denosumab-dssb, denosumab-mobz, denosumab-qbde, Acvybra, Bildyos, Bilprevda, Bomyntra, Boncresa, Conexxence, Degevma, Denbrayce, Enoby, Enwylma, Evfraxy, Izamby, Jubbonti, Jubereq, Junod, Kefdensis, Obodence, Osenvelt, Ospomyv, Osqay, Osvyrti, Oziltus, Ponlimsi, Stoboclo, Vevzuo, Wyost Xbonzy, Xbryk, Xtrenbo, Yaxwer, Zadenvi, Zvogra
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- /Schedule D
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Research
6,001 papers- Prevention and Management of Denosumab Discontinuation Rebound Fractures.Endocrinology and metabolism clinics of North America · 2024
- Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025
- Stopping Denosumab.Current osteoporosis reports · 2019
- Denosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach.Aging clinical and experimental research · 2025
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.Lancet (London, England) · 2015
via PubMed
Wikidata facts
Show 3 more facts
- World Health Organisation international non-proprietary name
- denosumab
- defined daily dose
- 0.33
- Commons category
- Denosumab
via Wikidata · CC0
~18 min read
Article
13 sectionsContents
- Medical uses
- Cancer
- Osteoporosis
- Mechanism of action
- Contraindications and interactions
- Adverse effects
- Society and culture
- Legal status
- United States
- European Union
- Canada
- References
- Further reading
Denosumab, sold under the brand name Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.
The most common side effects are joint and muscle pain in the arms or legs.
Connections
interferon gamma
Entity
peginterferon alfa-2a
Entity
pamidronic acid
Entity
interferon type I
Entity
TNF superfamily member 11
Protein
momelotinib
Entity
human
Entity
nitrogen
Entity
bone
Entity
calcium
Entity
International Standard Book Number
Entity
circulatory system
Entity
immunity
Entity
The New York Times
Entity
Wayback Machine
Entity
digital object identifier
Entity
infection
Entity
chemical formula
Entity
neurology
Entity
vitamin D
Entity